Lilly Unveils Promising Phase 1 Results for Ovarian Cancer ADC Targeting FRα at ASCO 2025 Eli Lilly showcases compelling Phase 1 data for its innovative FRα-targeting ADC treatment aimed at platinum-resistant ovarian cancer during the ASCO 2025 meeting.

Lilly Unveils Promising Phase 1 Results for Ovarian Cancer ADC Targeting FRα at ASCO 2025 #United_States #Indianapolis #Eli_Lilly #Ovarian_Cancer #FRα